Welcome to our dedicated page for Select Medical SEC filings (Ticker: SEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Select Medical Holdings Corporation SEC filings document the formal disclosures of a NYSE-listed healthcare services company with common stock traded under SEM. Its Form 8-K reports cover operating results and financial condition, material-event disclosures, capital-structure information, employment and compensation-related agreements, and Regulation FD communications.
Proxy materials and annual-meeting filings describe director elections, executive compensation votes, auditor ratification, board-structure proposals, stockholder meeting rights and voting outcomes. The filings also record governance matters and corporate reporting related to Select Medical's hospital and outpatient rehabilitation operations.
Select Medical Holdings (SEM) reported an insider equity award. The company’s Chief Accounting Officer received a grant of 20,000 shares of restricted stock on 10/28/2025 at $0 per share. According to the terms, the award will vest in full on October 28, 2029. Following the grant, the reporting person beneficially owns 54,254 shares, held directly.
Select Medical Holdings Corporation furnished a press release announcing financial results for the third quarter ended September 30, 2025. The materials were provided under Item 2.02 and are treated as furnished, not filed, under the Exchange Act.
The Board also declared a cash dividend of $0.0625 per share, payable on or about November 25, 2025 to stockholders of record as of the close of business on November 12, 2025. The press release with financial schedules was included as Exhibit 99.1.
Select Medical Holdings (SEM) reported Q3 results with revenue of $1,363,445 thousand, up from $1,271,582 thousand a year ago. Income from continuing operations, net of tax, was $44,180 thousand versus $41,276 thousand, and EPS from continuing operations was $0.23 versus $0.19. Adjusted EBITDA reached $111,655 thousand compared with $103,898 thousand.
By segment, revenue was $609,929 thousand in Critical Illness Recovery Hospitals, $328,607 thousand in Rehabilitation Hospitals, and $325,383 thousand in Outpatient Rehabilitation. For the nine months ended September 30, 2025, revenue was $4,056,196 thousand and income from continuing operations, net of tax, was $176,791 thousand, with EPS from continuing operations of $1.00. Operating cash flow for the period was $282,142 thousand, and capital expenditures were $170,125 thousand. Total debt had a carrying value of $1,772,149 thousand. As of September 30, 2025, SEM had 123,817,591 shares outstanding.
John F. Duggan, Executive Vice President and a director of Select Medical Holdings Corporation (SEM), reported beneficial ownership of 149,575 shares of the issuer's common stock. The filing discloses four grants of restricted stock: three grants of 25,000 shares (granted on November 1 of 2021, 2022 and 2023) and one grant of 50,000 shares (granted April 30, 2024). Each grant includes vesting schedules that generally fully vest on the fourth anniversary of the grant date, with a special one‑third vesting event noted on November 5, 2024, and other customary exceptions.
Select Medical Holdings Corporation (SEM) filed an 8-K reporting leadership changes. The filing references Item 5.02 and Item 7.01 and includes an exhibit: a press release dated September 2, 2025 announcing the appointment of Mr. Mullin as Chief Executive Officer and noting other changes involving long-tenured leaders. The 8-K indicates the company furnished written communications under Regulation FD and provided the press release as Exhibit 99.1. The disclosure signals a formal CEO transition and related leadership adjustments, documented through the company’s required SEC communication channels.